ULACNet-301, OPTIMO protocol: optimizing HPV vaccination regimen for cancer prevention in children and adolescents living with HIV

Supported by the National Institutes of Health (NIH)-National Cancer Institute (NCI), under award number U54 CA242977 (US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network -ULACNet). Merck, Sharp and Dohme (MSD) provides HPV vaccine, Gardasil-9, and partial funding for vacci...

Full description

Bibliographic Details
Authors: Pinto-Santini, Delia, Jalil, Emilia M., Fernandes, Giovana Teixeira, Hilaire, Genevieve, Kolevic, Lenka, Cabello, Robinson, Grinsztejn, Beatriz, Pape, William, Deschamps, Marie Marcelle, House, Margaret G., Brofsky, Emma, Sahasrabuddhe, Vikrant V., Dasgupta, Sayan, Pasalar, Siavash, Madeleine, Margaret M., Carter, Joseph, Prabhu, Priya R., Galloway, Denise, Duerr, Ann
Format: article
Status:Published version
Publication Date:2025
Country:Brasil
Institution:Fundação Oswaldo Cruz (FIOCRUZ)
Repository:Repositório Institucional da FIOCRUZ (ARCA)
Language:English
OAI Identifier:oai:arca.fiocruz.br:icict/68939
Online Access:https://arca.fiocruz.br/handle/icict/68939
Access Level:Open access
Keyword:HPV
HIV
Vaccination
Children
LMIC
Description
Summary:Supported by the National Institutes of Health (NIH)-National Cancer Institute (NCI), under award number U54 CA242977 (US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network -ULACNet). Merck, Sharp and Dohme (MSD) provides HPV vaccine, Gardasil-9, and partial funding for vaccine shipment. NCI-DCP (Division of Cancer Prevention) has previously peer reviewed this protocol. NCI co-authors serve as collaborators (Project Scientists) as part of this Cooperative Agreement (‘U’) grant award.

Similar Items